Safety and efficacy of allogeneic hematopoietic stem cell transplantation for refractory hematological malignancies with plerixafor-combined myeloablative conditioning
Phase of Trial: Phase IV
Latest Information Update: 08 Feb 2019
Price : $35 *
At a glance
- Drugs Plerixafor (Primary) ; Antineoplastics
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 04 Feb 2019 Status changed from active, no longer recruiting to completed.
- 05 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 10 Dec 2013 New trial record